Biologics CDMO market size to increase by USD 13.26 billion from 2022 to 2027: Strong research and development pipeline of biologics therapeutics to boost market growth - Technavio

News provided by

Mar 02, 2023, 17:05 ET

NEW YORK, March 2, 2023 /PRNewswire/ -- The biologics CDMO market is estimated to accelerate at a CAGR of 13.97% and register an incremental growth of USD 13.26 billion during the forecast period. The strong research and development pipeline of biologics therapeutics is driving the market growth. Biologics are highly efficient in treating severe infections, malignancies, and immunological and hormonal disorders, which is encouraging manufacturers to invest in R&D. Many research institutes are engaged in developing novel biologics through industrial collaborations. Therefore, rising investments in research will fuel the market growth during the forecast period. For more insights on the historic (2017 to 2021) and forecast market size (2023 to 2027) - Download a PDF sample report

Technavio has announced its latest market research report titled Global Biologics CDMO Market 2023-2027

What`s New for 2023?

Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
Global competitiveness and key competitor positions
Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial

Regional analysis

Based on region, the global biologics CDMO market is segmented into North America, Europe, Asia, and Rest Of World (ROW). North America is estimated to account for 46% of the growth of the global market over the forecast period. The provision of reimbursements for biologics by the US government, rising patient awareness about the benefits of biologics, vendor collaborations, and the increasing prevalence of chronic diseases in the US are driving the growth of the market in North America.

Company profiles

The biologics CDMO market report includes information on the key products and recent developments of leading vendors, including:

AbbVie Inc.: The company offers biologics CDMO such as cell line development and cGMP manufacturing.
Binex Co. Ltd.: The company offers biologics CDMO such as microbial fermentation and mammalian cell culture lines.
Boehringer Ingelheim International GmbH: The company offers biologics CDMO such as biopharmaceutical contract development and manufacturing expertise.
Bora Pharmaceuticals Co. Ltd.: The company offers biologics CDMO such as pharmaceutical development and clinical manufacturing.
Catalent Inc.: The company offers biologics CDMO such as OneBio Integrated suite.

Market dynamics

The market is driven by factors such as the availability of cost-efficient resources in emerging markets, strong research and development pipeline of biologics therapeutics, and the growing need to focus on core competencies. However, capacity utilization and constraints are hindering the market growth.

Market segmentation

Based on type, the market is segmented into mammalian and microbial.
Based on product type, the market is segmented into biologics and biosimilars.
Based on geography, the market is segmented into North America, Europe, Asia, and Rest Of World (ROW).
Get insights on the market contribution of various segments including country and region wise, historic (2017 to 2021) and forecast market size (2023 to 2027) -Request a sample

Why buy?

Add credibility to strategy
Analyzes competitor's offerings
Get a holistic view of the market

Grow your profit margin with Technavio – Buy the report!

Related Reports:

The cancer biologics market size is expected to increase by USD 34.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.91%. Furthermore, this report extensively covers cancer biologics market segmentation by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

The orthobiologics market is estimated to grow at a CAGR of 7.88% between 2022 and 2027. The size of the market is forecast to increase by USD 2,638.44 million. This report extensively covers market segmentation by application (spinal fusion, reconstructive surgery, trauma repair, and others), product (bone graft substitutes, viscosupplementation, and stem cells), and geography (North America, Europe, Asia, and the Rest of World (ROW)).

Gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

What are the key data covered in this biologics CDMO market report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the biologics CDMO market between 2023 and 2027
Precise estimation of the biologics CDMO market size and its contribution to the parent market
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
Thorough analysis of the market's competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of biologics CDMO market vendors

Biologics CDMO Market Scope
Report Coverage	Details
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 13.97%
Market growth 2023-2027	USD 13.26 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	12.6
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 46%
Key countries	US, Germany, France, China, Japan, Canada, Mexico, Italy, Spain, Australia, and South Korea
Competitive landscape	Leading vendors, market positioning of vendors, competitive strategies, and industry risks
Key companies profiled	3P BIOPHARMACEUTICALS S.L.U., AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd., Catalent Inc., Cytovance Biologics, Evonik Industries AG, FUJIFILM Holdings Corp, Grifols SA, JRS PHARMA GmbH and Co. KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., KLOCKE GROUP, Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc.
Market dynamics	Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio health care market reports

Table of contents:

1 Executive Summary

1.1 Market overview

Exhibit 01: Executive Summary – Chart on Market Overview
Exhibit 02: Executive Summary – Data Table on Market Overview
Exhibit 03: Executive Summary – Chart on Global Market Characteristics
Exhibit 04: Executive Summary – Chart on Market by Geography
Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
Exhibit 06: Executive Summary – Chart on Market Segmentation by Product Type
Exhibit 07: Executive Summary – Chart on Incremental Growth
Exhibit 08: Executive Summary – Data Table on Incremental Growth
Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem

Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition

Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis

Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027

Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global biologics CDMO market 2017 - 2021

Exhibit 18: Historic Market Size – Data Table on Global biologics CDMO market 2017 - 2021 ($ billion)

4.2 Type Segment Analysis 2017 - 2021

Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ billion)

4.3 Product type Segment Analysis 2017 - 2021

Exhibit 20: Historic Market Size – Product type Segment 2017 - 2021 ($ billion)

4.4 Geography Segment Analysis 2017 - 2021

Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

4.5 Country Segment Analysis 2017 - 2021

Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary

Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers

Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers

Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants

Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes

Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry

Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition

Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Type

6.1 Market segments

Exhibit 30: Chart on Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Type - Market share 2022-2027 (%)

6.2 Comparison by Type

Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type

6.3 Mammalian - Market size and forecast 2022-2027

Exhibit 34: Chart on Mammalian - Market size and forecast 2022-2027 ($ billion)
Exhibit 35: Data Table on Mammalian - Market size and forecast 2022-2027 ($ billion)
Exhibit 36: Chart on Mammalian - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Mammalian - Year-over-year growth 2022-2027 (%)

6.4 Microbial - Market size and forecast 2022-2027

Exhibit 38: Chart on Microbial - Market size and forecast 2022-2027 ($ billion)
Exhibit 39: Data Table on Microbial - Market size and forecast 2022-2027 ($ billion)
Exhibit 40: Chart on Microbial - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Microbial - Year-over-year growth 2022-2027 (%)

6.5 Market opportunity by Type

Exhibit 42: Market opportunity by Type ($ billion)

7 Market Segmentation by Product Type

7.1 Market segments

Exhibit 43: Chart on Product Type - Market share 2022-2027 (%)
Exhibit 44: Data Table on Product Type - Market share 2022-2027 (%)

7.2 Comparison by Product Type

Exhibit 45: Chart on Comparison by Product Type
Exhibit 46: Data Table on Comparison by Product Type

7.3 Biologics - Market size and forecast 2022-2027

Exhibit 47: Chart on Biologics - Market size and forecast 2022-2027 ($ billion)
Exhibit 48: Data Table on Biologics - Market size and forecast 2022-2027 ($ billion)
Exhibit 49: Chart on Biologics - Year-over-year growth 2022-2027 (%)
Exhibit 50: Data Table on Biologics - Year-over-year growth 2022-2027 (%)

7.4 Biosimilars - Market size and forecast 2022-2027

Exhibit 51: Chart on Biosimilars - Market size and forecast 2022-2027 ($ billion)
Exhibit 52: Data Table on Biosimilars - Market size and forecast 2022-2027 ($ billion)
Exhibit 53: Chart on Biosimilars - Year-over-year growth 2022-2027 (%)
Exhibit 54: Data Table on Biosimilars - Year-over-year growth 2022-2027 (%)

7.5 Market opportunity by Product Type

Exhibit 55: Market opportunity by Product Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview

Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation

Exhibit 57: Chart on Market share by geography 2022-2027 (%)
Exhibit 58: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison

Exhibit 59: Chart on Geographic comparison
Exhibit 60: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2022-2027

Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.4 Europe - Market size and forecast 2022-2027

Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027

Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027

Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 US - Market size and forecast 2022-2027

Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)

9.8 China - Market size and forecast 2022-2027

Exhibit 81: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 82: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 83: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on China - Year-over-year growth 2022-2027 (%)

9.9 Germany - Market size and forecast 2022-2027

Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.10 France - Market size and forecast 2022-2027

Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ billion)
Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ billion)
Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%)

9.11 Japan - Market size and forecast 2022-2027

Exhibit 93: Chart on Japan - Market size and forecast 2022-2027 ($ billion)
Exhibit 94: Data Table on Japan - Market size and forecast 2022-2027 ($ billion)
Exhibit 95: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on Japan - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography

Exhibit 97: Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges

Exhibit 98: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape

Exhibit 99: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption

Exhibit 100: Overview on factors of disruption

11.4 Industry risks

Exhibit 101: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered

Exhibit 102: Vendors covered

12.2 Market positioning of vendors

Exhibit 103: Matrix on vendor position and classification

12.3 AbbVie Inc.

Exhibit 104: AbbVie Inc. - Overview
Exhibit 105: AbbVie Inc. - Product / Service
Exhibit 106: AbbVie Inc. - Key news
Exhibit 107: AbbVie Inc. - Key offerings

12.4 Binex Co. Ltd.

Exhibit 108: Binex Co. Ltd. - Overview
Exhibit 109: Binex Co. Ltd. - Product / Service
Exhibit 110: Binex Co. Ltd. - Key offerings

12.5 Boehringer Ingelheim International GmbH

Exhibit 111: Boehringer Ingelheim International GmbH - Overview
Exhibit 112: Boehringer Ingelheim International GmbH - Business segments
Exhibit 113: Boehringer Ingelheim International GmbH - Key news
Exhibit 114: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 115: Boehringer Ingelheim International GmbH - Segment focus

12.6 Bora Pharmaceuticals Co. Ltd.

Exhibit 116: Bora Pharmaceuticals Co. Ltd. - Overview
Exhibit 117: Bora Pharmaceuticals Co. Ltd. - Product / Service
Exhibit 118: Bora Pharmaceuticals Co. Ltd. - Key offerings

12.7 Catalent Inc.

Exhibit 119: Catalent Inc. - Overview
Exhibit 120: Catalent Inc. - Business segments
Exhibit 121: Catalent Inc. - Key news
Exhibit 122: Catalent Inc. - Key offerings
Exhibit 123: Catalent Inc. - Segment focus

12.8 Evonik Industries AG

Exhibit 124: Evonik Industries AG - Overview
Exhibit 125: Evonik Industries AG - Business segments
Exhibit 126: Evonik Industries AG - Key news
Exhibit 127: Evonik Industries AG - Key offerings
Exhibit 128: Evonik Industries AG - Segment focus

12.9 FUJIFILM Holdings Corp

Exhibit 129: FUJIFILM Holdings Corp - Overview
Exhibit 130: FUJIFILM Holdings Corp - Business segments
Exhibit 131: FUJIFILM Holdings Corp - Key offerings
Exhibit 132: FUJIFILM Holdings Corp - Segment focus

12.10 Grifols SA

Exhibit 133: Grifols SA - Overview
Exhibit 134: Grifols SA - Business segments
Exhibit 135: Grifols SA - Key offerings
Exhibit 136: Grifols SA - Segment focus

12.11 JRS PHARMA GmbH and Co. KG

Exhibit 137: JRS PHARMA GmbH and Co. KG - Overview
Exhibit 138: JRS PHARMA GmbH and Co. KG - Product / Service
Exhibit 139: JRS PHARMA GmbH and Co. KG - Key offerings

12.12 Lonza Group Ltd.

Exhibit 140: Lonza Group Ltd. - Overview
Exhibit 141: Lonza Group Ltd. - Business segments
Exhibit 142: Lonza Group Ltd. - Key news
Exhibit 143: Lonza Group Ltd. - Key offerings
Exhibit 144: Lonza Group Ltd. - Segment focus

12.13 Novartis AG

Exhibit 145: Novartis AG - Overview
Exhibit 146: Novartis AG - Business segments
Exhibit 147: Novartis AG - Key offerings
Exhibit 148: Novartis AG - Segment focus

12.14 Rentschler Biopharma SE

Exhibit 149: Rentschler Biopharma SE - Overview
Exhibit 150: Rentschler Biopharma SE - Product / Service
Exhibit 151: Rentschler Biopharma SE - Key offerings

12.15 Samsung Biologics Co. Ltd.

Exhibit 152: Samsung Biologics Co. Ltd. - Overview
Exhibit 153: Samsung Biologics Co. Ltd. - Product / Service
Exhibit 154: Samsung Biologics Co. Ltd. - Key offerings

12.16 Toyobo Co. Ltd.

Exhibit 155: Toyobo Co. Ltd. - Overview
Exhibit 156: Toyobo Co. Ltd. - Business segments
Exhibit 157: Toyobo Co. Ltd. - Key offerings
Exhibit 158: Toyobo Co. Ltd. - Segment focus

12.17 WuXi Biologics Cayman Inc.

Exhibit 159: WuXi Biologics Cayman Inc. - Overview
Exhibit 160: WuXi Biologics Cayman Inc. - Product / Service
Exhibit 161: WuXi Biologics Cayman Inc. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist

Exhibit 162: Inclusions checklist
Exhibit 163: Exclusions checklist

13.3 Currency conversion rates for US$

Exhibit 164: Currency conversion rates for US$

13.4 Research methodology

Exhibit 165: Research methodology
Exhibit 166: Validation techniques employed for market sizing
Exhibit 167: Information sources

13.5 List of abbreviations

Exhibit 168: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio